{
    "organizations": [],
    "uuid": "371c575628ab768d74802f0981852be00b4adffc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-jr-131-long-acting-erythropoiesis/brief-jr-131-long-acting-erythropoiesis-stimulating-agent-demonstrates-equivalence-in-phase-iii-study-idUSL3N1PC2GC",
    "ord_in_thread": 0,
    "title": "BRIEF-JR-131, long-acting erythropoiesis-stimulating agent, demonstrates equivalence in phase III study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 17 (Reuters) - Kissei Pharmaceutical Co Ltd\n* Says it and JCR Pharmaceuticals Co Ltd jointly announced positive results of the phase III study for JR-131, a proposed biosimilar to darbepoetin alfa, a long-acting erythropoiesis-stimulating agent for the treatment of renal anemia\n* In the Phase III study initiated in August 2016, JR-131 demonstrated equivalence in efficacy and safety compared with darbepoetin\n* Accordingly, in a primary endpoint of efficacy, the equivalence was verified for variations in hemoglobin concentration and the similarity with regard to the safety profile was confirmed\nSource text in Japanese: goo.gl/eXovsF\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-01-17T14:29:00.000+02:00",
    "crawled": "2018-01-18T16:03:05.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "kissei",
        "pharmaceutical",
        "co",
        "ltd",
        "say",
        "jcr",
        "pharmaceutical",
        "co",
        "ltd",
        "jointly",
        "announced",
        "positive",
        "result",
        "phase",
        "iii",
        "study",
        "proposed",
        "biosimilar",
        "darbepoetin",
        "alfa",
        "agent",
        "treatment",
        "renal",
        "anemia",
        "phase",
        "iii",
        "study",
        "initiated",
        "august",
        "demonstrated",
        "equivalence",
        "efficacy",
        "safety",
        "compared",
        "darbepoetin",
        "accordingly",
        "primary",
        "endpoint",
        "efficacy",
        "equivalence",
        "verified",
        "variation",
        "hemoglobin",
        "concentration",
        "similarity",
        "regard",
        "safety",
        "profile",
        "confirmed",
        "source",
        "text",
        "japanese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}